Mirati Therapeutics (NASDAQ:MRTX) Downgraded by Leerink Partnrs
Leerink Partnrs downgraded shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from an outperform rating to a market perform rating in a research report sent to investors on Tuesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Mirati Therapeutics’ Q4 2023 earnings at ($2.24) EPS, FY2023 earnings at ($10.86) EPS, FY2024 earnings at ($9.25) […]
More Stories
US Forces Prevent 70 Tankers From Entering or Leaving Iranian Ports
By Naveen Athrappully The U.S. military is currently blocking more than 70 tankers from entering or leaving Iranian ports amid...
Iran’s Oil Storage Clock Is About to Run Out
By John Haughey The “storage clock” is ticking as tankers that exported 3.2 million barrels per day (bpd) of crude...
Wall Street Review: Stock Rally Broadens as S&P 500, Nasdaq Hit New Record Highs
By Panos Mourdoukoutas Wall Street’s multi-week rally turned into an “everything rally” this week amid lower oil prices, steady bond...
FIFA Triples Price to $32,970 for Its Best Available Tickets to the World Cup Final
By The Associated Press FIFA tripled the price of its best available tickets to the World Cup final, making $32,970...
Fallout Nuka Girl: Release Date, Pricing and More
Have you ever explored the world of the Fallout video gaming series? If yes, you must have probably seen the...
US to Host New Israel–Lebanon Peace Talks
By Ryan Morgan The United States will again host a set of talks between Israeli and Lebanese delegations on May...